Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of three-dimensional right ventricular function and reverse remodelling in patients undergoing percutaneous mitral valve repair for functional mitral regurgitation: insights from a multicentre Italian registry.

Acta cardiologica·2025
Same author

Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis.

ESC heart failure·2024
Same author

A targeted proteomics approach to amyloidosis typing.

Clinical mass spectrometry (Del Mar, Calif.)·2024
Same author

Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study.

Reviews in cardiovascular medicine·2024
Same author

Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.

European journal of preventive cardiology·2024
Same author

Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy.

Circulation·2024
Same journal

Giornale italiano di cardiologia (2006)·2026
Same journal

[Green paper ANMCO: Environmental sustainability in cardiology: a shared commitment of healthcare professionals].

Giornale italiano di cardiologia (2006)·2026
Same journal

[Bempedoic acid in real-world clinical practice: baseline and 8-week data from the Italian prospective, non-interventional MILOS study].

Giornale italiano di cardiologia (2006)·2026
Same journal

[Ranolazine: established indications and emerging therapeutic potential].

Giornale italiano di cardiologia (2006)·2026
Same journal

[Kawasaki disease: the update of American Heart Association guidelines. What adult cardiologists need to know].

Giornale italiano di cardiologia (2006)·2026
Same journal

[The application of artificial intelligence in arrhythmology].

Giornale italiano di cardiologia (2006)·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

[Gender effect on cardiomyopathy].

Elena Biagini1, Alessandra Berardini, Maddalena Graziosi

  • 1Universita di Bologna, Bologna. biaginielena@libero.it

Giornale Italiano Di Cardiologia (2006)
|May 25, 2012
PubMed
Summary
This summary is machine-generated.

Gender significantly impacts cardiomyopathy presentation and outcomes. Research is ongoing to understand sex-specific differences and develop targeted therapies for conditions like peripartum cardiomyopathy.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Experiment Videos

Last Updated: May 22, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Area of Science:

  • Cardiology
  • Genetics
  • Reproductive Medicine

Background:

  • The influence of gender on cardiomyopathy clinical manifestations, treatment responses, and prognosis is not fully understood.
  • While some sex-specific cardiomyopathies exist, like peripartum cardiomyopathy, the broader impact of gender requires further investigation.
  • Existing research highlights differences in X-linked and mitochondrial inherited cardiomyopathies between sexes.

Purpose of the Study:

  • To explore the multifaceted role of gender in the pathophysiology and clinical course of various cardiomyopathies.
  • To review current knowledge on sex-specific differences in cardiomyopathy presentation, risk factors, and therapeutic strategies.
  • To examine the implications of cardiomyopathies on pregnancy and the management of affected women.

Main Methods:

  • Literature review of studies investigating gender differences in cardiomyopathy.
  • Analysis of clinical data on sex-specific manifestations and prognoses.
  • Examination of genetic and hormonal influences on cardiomyopathy development and progression.

Main Results:

  • Peripartum cardiomyopathy is a female-specific condition potentially treatable with prolactin inhibitors.
  • X-chromosome inactivation leads to varied manifestations in female carriers of X-linked cardiomyopathies.
  • Female hormones may offer premenopausal protection against myocardial conditions like hypertrophic cardiomyopathy and amyloidosis.
  • Pregnancy in women with pre-existing cardiomyopathies poses risks due to hemodynamic changes, requiring careful management.

Conclusions:

  • Gender plays a critical role in cardiomyopathy, influencing disease presentation, progression, and treatment efficacy.
  • Further research into sex-specific mechanisms is crucial for personalized therapeutic approaches.
  • Specialized care is essential for pregnant women with cardiomyopathies, particularly those with significant cardiac dysfunction.